Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
AssigneeIovance Biotherapeutics, Inc.
InventorsSeth Wardell, James Bender, Michael T. Lotze
Life of this patent
Estimating the term…
Abstract
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
Claims30
A tumor infiltrating lymphocyte (TIL) pharmaceutical composition comprising:
- i) an expanded population of tumor infiltrating lymphocytes (TILs), and
- ii) a pharmaceutically acceptable carrier;
- wherein the expanded population of TILs is capable of exhibiting increased IFN-γ secretion by at least one-fold in vitro as compared to a non-expanded population of TILs.
A tumor infiltrating lymphocyte (TIL) pharmaceutical composition comprising:
- i) an expanded population of tumor infiltrating lymphocytes (TILs), and
- ii) a pharmaceutically acceptable carrier;
- wherein the expanded population of TILs is capable of exhibiting IFN-γ secretion greater than 200 pg/ml.
An expanded population of tumor infiltrating lymphocytes (TILs) that is capable of exhibiting IFN-γ secretion greater than 200 pg/ml.
An expanded population of tumor infiltrating lymphocytes (TILs) that is capable of exhibiting increased IFN-γ secretion by at least one-fold in vitro as compared to a non-expanded population of TILs.
Dependencies are inferred from the claim text.